Objectives:This study was performed based on the hypothesis that the interindividual differences
in clinical response to atypical antipsychotics might be associated with serotonin 2A receptor(5-HT2A)
gene and(or) dopamine D3 receptor(DRD3) gene poly...
Objectives:This study was performed based on the hypothesis that the interindividual differences
in clinical response to atypical antipsychotics might be associated with serotonin 2A receptor(5-HT2A)
gene and(or) dopamine D3 receptor(DRD3) gene polymorphisms.
Methods:Seventy-five patients(39 men, 36 women) who met DSM-IV criteria for Schizophrenia at
the Asan Medical Center were selected for the analysis of the medical records and subsequent interview.
A written informed consent was obtained prior to the study and the privacy protection was kept throughout
the course. Clinical Global Impression(CGI) Scale was applied after 4 weeks of treatment to assess
the response to atypical antipsychotics. All patients in this study were administered olanzapine(n=39),
risperidone(n=52) or clozapine(n=4). According to CGI scale, the patients were classified in 7 groups;
very much improvement;much improvement;minimal improvement;no change;minimal worsening;
much worsening;very much worsening. The first and second groups were regarded as responders
while the other groups were non-responders. Patients were genotyped for 5-HT2A by PCR(Msp
I) for detection of T102 and C102 alleles. And they were also genotyped for DRD3 Ser9Gly polymorphism
by PCR(Bal I). We conducted the statistical analyses to detect association between responders and non
responders with chi-square tests.
Results:The patients who were shown no or minimally improved patients were sorted to nonresponders(
n=42, men 24, women 18) and the other patients shown much or very much improved were
grouped as responders(n=33, men 15, women 18). The differences in demographic variables(age, sex),
age of onset, and duration of illness were not statistically significant between the two groups. T102
allele is more frequent in non-responders(56.0%) than responders(45.5%), however, this difference
is not statistically significant(p=0.20). Gly9 allele is near equal between non-responders and responders
(65.5%, 65.2%). Genotype frequencies of the two groups also is not a statistically significant for 5-
HT2A T102C(p=0.28) and DRD3 Ser9Gly(p=0.90).
Conclusion:These results do not show significant associations among 5-HT2A gene, DRD3 gene
and clinical response to atypical antipsychotics. On the assumption that responses to atypical antipsychotics
are mediated by these two receptors, we can draw two possibilities. First, 5-HT2A and DRD3 genes may
not be the functional variants related with responses to atypical antipsychotics. Second possibility is
that the unknown variations which might be in linkage disequilibrium with the 5-HT2A T102C polymorphism
and DRD3 Ser9Gly polymorphism may be associated with the response to atypical antipsychotics
in schizophrenia. However, it is possible that the small number of subjects and ethnic difference of allele
frequency of marker polymorphism could induce false negative results.